Acquiring evidence for precision prostate cancer care

por Mateo, J., Carreira, S., de Bono, J. S.
Publicado en Ann Oncol (2017)

Long term follow up of patients with repaired aortic coarctations

por de Bono, J P, Freeman, L J
Publicado 2005

Targeting IGF-1R: throwing out the baby with the bathwater?

por Basu, B, Olmos, D, de Bono, J S
Publicado 2011

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

por Ang, J E, Olmos, D, de Bono, J S
Publicado 2009

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

por Stewart, A., Thavasu, P., de Bono, J. S., Banerji, U.
Publicado en Ann Oncol (2015)

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

por Lheureux, S., Denoyelle, C., Ohashi, P. S., De Bono, J. S., Mottaghy, F. M.
Publicado en Eur J Nucl Med Mol Imaging (2017)

Clinical anticancer drug development: targeting the cyclin-dependent kinases

por Benson, C, Kaye, S, Workman, P, Garrett, M, Walton, M, de Bono, J
Publicado 2005

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

por Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S
Publicado 2008

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

por Attard, G, Sarker, D, Reid, A, Molife, R, Parker, C, de Bono, J S
Publicado 2006

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience

por Olmos, D, Arkenau, H-T, Ang, J E, de Bono, J S, Judson, I, Kaye, S B
Publicado 2008

Drugs and the exercise test.

por Muir, K. W., Rodger, J. C., DeBono, J. S., McDonald, H., Irving, J. B.
Publicado 1992

The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

por Kumar, R, Geuna, E, Michalarea, V, Guardascione, M, Naumann, U, Lorente, D, Kaye, S B, de Bono, J S
Publicado en Br J Cancer (2015)

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

por Wilbaux, M, Tod, M, De Bono, J, Lorente, D, Mateo, J, Freyer, G, You, B, Hénin, E
Publicado en CPT Pharmacometrics Syst Pharmacol (2015)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado 2009

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

por Brunetto, A T, Sarker, D, Papadatos-Pastos, D, Fehrmann, R, Kaye, S B, Johnston, S, Allen, M, De Bono, J S, Swanton, C
Publicado 2010

Telemetric analysis of haemodynamic regulation during voluntary exercise training in mouse models

por Adlam, D., De Bono, J. P., Danson, E. J., Zhang, M. H., Casadei, B., Paterson, D. J., Channon, K. M.
Publicado en Exp Physiol (2011)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

por Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O.
Publicado 2013

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer

por Thiery-Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Thangavelu, K., Ozatilgan, A., Poole, E.M., Eisenberger, M., de Bono, J.
Publicado en ESMO Open (2021)

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

por Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S
Publicado 2014

A decade of clinical development of PARP inhibitors in perspective

por Mateo, J, Lord, C J, Serra, V, Tutt, A, Balmaña, J, Castroviejo-Bermejo, M, Cruz, C, Oaknin, A, Kaye, S B, de Bono, J S
Publicado en Ann Oncol (2019)